ConductScience.org, home

Paper42416752

Targeting Mouse Double Minute 2 Homolog (MDM2) Oncogene in Breast Adenocarcinoma.

Niotis A and 7 others. Maedica (Bucur), 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Targeting Mouse Double Minute 2 Homolog (MDM2) Oncogene in Breast Adenocarcinoma. Papers, record 42416752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42416752

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeting Mouse Double Minute 2 Homolog (MDM2) Oncogene in Breast Adenocarcinoma.
PubMed
Journal
Maedica (Bucur)
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Niotis AAthanasios
2Mastronikoli SSofianiki
3Spyropoulou DDespoina
4Adamopoulou MMaria
5Fotiades PPanagiotis
6Vylliotis AAntonios
7Tsantoulas AAlexandros
8Tsiambas EEvangelos

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References50

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
18048160The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger.Trends Biochem Sci1994https://conductscience.org/library/papers/8048160PubMed
241991605Mitochondrial translocation of MDM2 and TFAM reprograms metabolism in treatment-refractory cancers.NPJ Precis Oncol2026https://conductscience.org/library/papers/41991605PubMed
318834305Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.Annu Rev Pharmacol Toxicol2009https://conductscience.org/library/papers/18834305PubMed
441528114Cancer statistics, 2026.CA Cancer J Clin2026https://conductscience.org/library/papers/41528114PubMed
536987836Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS.Future Oncol2023https://conductscience.org/library/papers/36987836PubMed
628669344p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.Curr Cancer Drug Targets2018https://conductscience.org/library/papers/28669344PubMed
738736923Management of an Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma of the Left Laterocervical Region: Report of a Rare Case.Maedica (Bucur)2024https://conductscience.org/library/papers/38736923PubMed
817116689Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.Mol Cell Biol2007https://conductscience.org/library/papers/17116689PubMed
916107876MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation.EMBO J2005https://conductscience.org/library/papers/16107876PubMed
1041657798Comprehensive profiling of somatic alterations and HRD characteristics in Chinese germline BRCA-mutated breast cancer patients.Am J Cancer Res2026https://conductscience.org/library/papers/41657798PubMed
112026149Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.EMBO J1991https://conductscience.org/library/papers/2026149PubMed
1240191734Targeting MDM2-p53 interaction for breast cancer therapy.Oncol Res2025https://conductscience.org/library/papers/40191734PubMed
1325396320Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.J Med Chem2015https://conductscience.org/library/papers/25396320PubMed
1432300595Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?Front Cell Dev Biol2020https://conductscience.org/library/papers/32300595PubMed
1525739118Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.Oncotarget2015https://conductscience.org/library/papers/25739118PubMed
1617170710The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity.EMBO J2007https://conductscience.org/library/papers/17170710PubMed
178529093Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene.Mol Med1995https://conductscience.org/library/papers/8529093PubMed
189430646Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein.EMBO J1998https://conductscience.org/library/papers/9430646PubMed
1942056242Ginkgetin enhances the antitumor effect of Taxol on human breast cancer MCF-7 cells via ferroptosis mediated by the MDM2-p53-YAP1 axis.Sci Rep2026https://conductscience.org/library/papers/42056242PubMed
2021376230Hallmarks of cancer: the next generation.Cell2011https://conductscience.org/library/papers/21376230PubMed

See all 50 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42416752

GET https://conductscience.org/api/papers/v1/42416752/references?page=2